Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New test aims to improve doctor decisions for chronic illness

NCT ID NCT05192590

Knowledge-focused Sponsor: Qure Healthcare, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a new test (CDMT) helps primary care doctors make better decisions for patients with cardiometabolic syndrome. 247 board-certified physicians participated, with some using the test and others not. Researchers measured the quality of care and expected costs to see if the test improves patient management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

247 people

The number who actually took part.

Started

Oct 2021

Finished

Feb 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects must meet the following criteria to be enrolled in the study: 1. Board-certified physician currently practicing in the following areas: 1. Internal medicine 2. Family medicine 2. Have practiced as a board-certified physician in internal or family medicine or greater than 2 but less than 30 years 3. Community / non-academic based practice setting 4. ≥ 40 patients under care weekly 5. Commonly treats patients with atrial fibrillation, coronary artery disease, congestive heart failure, diabetes, hypertension, and hyperlipidemia 6. Practicing in the U.S. 7. English-speaking 8. Access to the internet 9. Informed and voluntarily consented to be in the study Exclusion Criteria: 1. Non-English speaking 2. Practicing in an academic setting 3. Unable to access the internet 4. Not practicing in the U.S. 5. Do not voluntarily consent to be in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiometabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiometabolic syndrome

Contacts and locations

Locations

  • QURE Healthcare

    San Francisco, California, 94109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.